Expression of Target in Endometriotic Lesions

Endometriosis is a common gynecological disorder associated with chronic pelvic pain and infertility, which affects women of reproductive age worldwide. This study aims to investigate the expression patterns of specific molecules in tissue specimens obtained from patients with endometriosis. The investigators will compare the expression levels of these molecules between endometriotic lesions and normal tissue. The primary objective of this study is to elucidate the potential roles of these molecules in the pathogenesis of endometriosis.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Endometriosis Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Urogenital Diseases

Age range

18 year–50 year

Sex eligibility

Female

Study type

Observational

Primary location

Beijing Tsinghua Changgung Hospital

Beijing, Beijing Municipality, 102218, China

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Pathologically confirmed endometriosis via laparoscopy and histopathological examination
Complete clinical and pathological data available

Exclusion criteria

History of any malignant tumor

Treatment and study plan

Retrospective molecular expression analysis in endometriosis tissue specimens

Other

This study involves no prospective interventional measures for participants.

Primary outcomes

Expression levels of molecular in endometriotic lesions and adjacent normal tissue

Time frame: 6 months

Standardized pathological histology assessment method

Interested in participating?

Recruiting

Interested in participating?

Request Info

Sponsors and collaborators

Lead sponsor

Beijing Tsinghua Chang Gung Hospital

Other

Registry information

Official study title

To Investigate the Expression of Target in Endometriotic Lesions

Important dates

Study start: 2026
Primary completion: 2026
Study completion: 2027
First posted: Jul 9, 2026
Registry last updated: Jul 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting